Even if McKinsey doesn’t share confidential information, the firm’s decision to work simultaneously for drug companies and the FDA puts all parties in an awkward position at best. The FDA had already drawn fire for growing too close to Big Pharma. But it was the agency’s close collaboration with the drugmaker Biogen in promoting its controversial Alzheimer’s drug, aducanumab, that raised the most pointed questions about the FDA’s impartiality.
